7h agoThe FlyBEARISH 22General
Archived explainer. For the current picture see today's IOVA page.
Why Is IOVANCE BIOTHERAPEUT (IOVA) Stock Down Today?
By the Top Tier Newswire AI Desk · October 29, 2026 at 11:11 AM ET · reviewed against 9 wire stories
IOVANCE BIOTHERAPEUT (IOVA) is down -36.77% in the latest session. Our newswire has captured 9 stories on IOVA across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Iovance Biotherapeutics shares fell 36.77% to $9.37 on Thursday. The sharp decline followed the release of updated Phase 2 trial data for lifileucel in metastatic non-small-cell lung cancer, which showed an objective response rate consistent with prior reports but failed to sustain the pre-market rally.
What Happened
The company reported updated results from the IOV-LUN-202 trial, revealing a 24.6% objective response rate in 69 patients with non-squamous metastatic non-small-cell lung cancer. These figures were consistent with previously reported data, and Iovance also announced a new precision TIL strategy for second-line treatment. Prior to the official release, the stock had jumped more than 10% in after-hours trading on expectations of positive data. However, the broader market reaction was mixed, with the Federal Reserve holding interest rates steady at 3.75% to 4.00% in a 10-2 vote. The company scheduled a webcast for October 29, 2026, to discuss the TIL therapy data and its broader precision medicine strategy.
What The Data Shows
The stock opened at $16.38, a 10.6% gap up from the prior close of $14.81. It reached a session high of $17.21 at 7:00 AM ET before sliding to a session low of $9.35 by 11:10 AM ET. Trading volume reached 31.1 million shares, which is 1.9 times the three-month daily average. The stock has a market capitalization of $6.6 billion and is currently unprofitable, with a trailing twelve-month EPS of -0.71. Revenue grew 34.5% over the same period, while the net margin stood at -89.1%. The 52-week range extends from $1.76 to $15.37. Over the last eight sessions, the stock had moved up 4.2%. Unusual options activity included one notable print with $17,000 in call premium and no put premium. The stock printed five fresh 52-week highs and 17 fresh 52-week lows on October 29, 2026.
What To Watch
Iovance Biotherapeutics is scheduled to report its third quarter 2026 financial results on November 5, 2026.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IOVA by the numbers
Last: $9.37Session: -36.77%7 sessions: -35.09%Coverage: 9 stories / 7 sourcesAI sentiment: 56/100 (mixed)Mkt cap: $6.6B52w: $1.76 to $15.37
The headlines behind the move
7h agoGuruFocusBULLISH 74Product/PR
Iovance Biotherapeutics (IOVA) Reports Promising Phase 2 Trial Results for Lifileucel in mNSCLC
8h agoThe FlyBULLISH 58Product/PR
Iovance reports updated IOV-LUN-202 results for lifileucel in lung cancer
9h agoYahoo FinanceBEARISH 42General
Can Iovance Stock Fall 50%?
For questions about this article or underlying research, email [email protected].
10h agoGlobeNewswireBULLISH 63Product/PR
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are...
18h agoStocktwits NewsNEUTRAL 52Fed/CB
Dow, S&P 500, Nasdaq Futures Mixed After Fed Holds Rates Steady: GOOG, GOOGL, IOVA, MSFT, NOW In Focus
The Federal Reserve held rates steady at 3.75%-4.00% with a 10-2 vote, largely in line with market expectations.
20h agoStocktwits NewsBULLISH 74Product/PR
Why Did IOVA Stock Jump Over 10% After-Hours Today?
Iovance will share positive Phase 2 results for Lifileucel on Thursday, along with a precision-medicine update.
22h agoBusiness InsiderBULLISH 63Product/PR
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IOVA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IOVA move explainers: 2026-10-29 · 2026-10-19 · 2026-10-06 · 2026-09-30 · 2026-09-29 · 2026-08-24 · 2026-08-21 · 2026-08-20 · 2026-08-19 · 2026-08-06